This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEHA30LG_L.jpg
U.S. sales of the cocktail, REGEN-COV, approved for emergency use in non-hospitalized COVID-19 patients, were $676.7 million in the third quarter, compared with analysts’ estimates of $320.5 million.
The company also recorded additional revenue of $127 million from its collaboration with Roche, which sells the cocktail as Ronapreve outside the United States.
A sharp surge in COVID-19 cases led by the Delta variant caused a “tremendous acceleration” in use of the cocktail, Regeneron (NASDAQ:REGN) Chief Executive Officer Leonard Schleifer had said in August.
Regeneron delivered 300,000 doses of the 1.4 million additional doses that were ordered by the U.S. government in September for $2.94 billion. The company will supply the rest by Jan. 31.
Sales of eczema drug Dupixent, which are recorded by Sanofi (NASDAQ:SNY), rose 55% to $1.66 billion for the quarter.
Eylea, the company’s macular degeneration treatment, reported a 12% rise in sales to $1.47 billion.
Third-quarter revenue jumped 51% to $3.45 billion, while analysts had expected $2.82 billion, according to Refinitiv IBES data.
On an adjusted basis, the company earned $15.37 per share.
Regeneron’s shares were up 2.7% before the bell, set to add to the 35% gains recorded so far this year.
